BOSTON --(BUSINESS WIRE)--Aug. 28, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled

Completed multiple financings in 2019, including initial public offering, raising $184.7 million to fund clinical development of novel CNS pipeline Results from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track to report data in

BOSTON --(BUSINESS WIRE)--Aug. 6, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that Andrew Miller , Ph.D., founder and chief operating

BOSTON --(BUSINESS WIRE)--Jul. 2, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the closing of its initial public offering of 6,414,842

BOSTON --(BUSINESS WIRE)--Jun. 27, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock.

$12 million in extension funding announced Karuna awarded U.S. Patent covering lead product candidate, KarXT BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc . (“Karuna”) focused on targeting muscarinic receptors for the treatment of neuropsychiatric disorders, including psychosis in

Proceeds will be used to advance clinical development of lead product candidate, KarXT, for additional indications beyond the ongoing Phase 2 clinical trial in schizophrenia and for expansion of the pipeline BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc.

BOSTON--( BUSINESS WIRE )-- Karuna Pharmaceuticals, Inc.  (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, as well as pain, today announced the appointment of Christian (Chris) Felder,

BOSTON--( BUSINESS WIRE )-- Karuna Pharmaceuticals, Inc.  (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, as well as pain, today announced that Mr.